Role of proteinase-activated receptor-2 in anti-bacterial and immunomodulatory effects of interferon-γ on human neutrophils and monocytes

Victoria M. Shpacovitch, Micha Feld, Dirk Holzinger, Makiko Kido, Morley D. Hollenberg, Francesca Levi-Schaffer, Nathalie Vergnolle, Stephan Ludwig, Johannes Roth, Thomas Luger, Martin Steinhoff

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Recent studies show that proteinase-activated receptor-2 (PAR2) contributes to the development of inflammatory responses. However, investigations into the precise role of PAR2 activation in the anti-microbial defence of human leucocytes are just beginning. We therefore evaluated the contribution of PAR2 to the anti-microbial response of isolated human innate immune cells. We found that PAR2 agonist, acting alone, enhances phagocytosis of Staphylococcus aureus and killing of Escherichia coli by human leucocytes, and that the magnitude of the effect is similar to that of interferon-γ (IFN-γ). However, co-application of PAR2-cAP and IFN-γ did not enhance the phagocytic and bacteria-killing activity of leucocytes beyond that triggered by either agonist alone. On the other hand, IFN-γ enhances PAR2 agonist-induced monocyte chemoattractant protein 1 (MCP-1) secretion by human neutrophils and monocytes. Furthermore, phosphoinositide-3 kinase and janus kinase molecules are involved in the synergistic effect of PAR2 agonist and IFN-γ on MCP-1 secretion. Our findings suggest a potentially protective role of PAR2 agonists in the anti-microbial defence established by human monocytes and neutrophils.

Original languageEnglish
Pages (from-to)329-339
Number of pages11
JournalImmunology
Volume133
Issue number3
DOIs
Publication statusPublished - Jul 1 2011

Fingerprint

PAR-2 Receptor
Interferons
Monocytes
Neutrophils
Leukocytes
Janus Kinases
1-Phosphatidylinositol 4-Kinase
Chemokine CCL2
Phagocytosis
Staphylococcus aureus
Escherichia coli
Bacteria

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Role of proteinase-activated receptor-2 in anti-bacterial and immunomodulatory effects of interferon-γ on human neutrophils and monocytes. / Shpacovitch, Victoria M.; Feld, Micha; Holzinger, Dirk; Kido, Makiko; Hollenberg, Morley D.; Levi-Schaffer, Francesca; Vergnolle, Nathalie; Ludwig, Stephan; Roth, Johannes; Luger, Thomas; Steinhoff, Martin.

In: Immunology, Vol. 133, No. 3, 01.07.2011, p. 329-339.

Research output: Contribution to journalArticle

Shpacovitch, VM, Feld, M, Holzinger, D, Kido, M, Hollenberg, MD, Levi-Schaffer, F, Vergnolle, N, Ludwig, S, Roth, J, Luger, T & Steinhoff, M 2011, 'Role of proteinase-activated receptor-2 in anti-bacterial and immunomodulatory effects of interferon-γ on human neutrophils and monocytes', Immunology, vol. 133, no. 3, pp. 329-339. https://doi.org/10.1111/j.1365-2567.2011.03443.x
Shpacovitch, Victoria M. ; Feld, Micha ; Holzinger, Dirk ; Kido, Makiko ; Hollenberg, Morley D. ; Levi-Schaffer, Francesca ; Vergnolle, Nathalie ; Ludwig, Stephan ; Roth, Johannes ; Luger, Thomas ; Steinhoff, Martin. / Role of proteinase-activated receptor-2 in anti-bacterial and immunomodulatory effects of interferon-γ on human neutrophils and monocytes. In: Immunology. 2011 ; Vol. 133, No. 3. pp. 329-339.
@article{bfc289705e0e40bda09bf3218afcbe3a,
title = "Role of proteinase-activated receptor-2 in anti-bacterial and immunomodulatory effects of interferon-γ on human neutrophils and monocytes",
abstract = "Recent studies show that proteinase-activated receptor-2 (PAR2) contributes to the development of inflammatory responses. However, investigations into the precise role of PAR2 activation in the anti-microbial defence of human leucocytes are just beginning. We therefore evaluated the contribution of PAR2 to the anti-microbial response of isolated human innate immune cells. We found that PAR2 agonist, acting alone, enhances phagocytosis of Staphylococcus aureus and killing of Escherichia coli by human leucocytes, and that the magnitude of the effect is similar to that of interferon-γ (IFN-γ). However, co-application of PAR2-cAP and IFN-γ did not enhance the phagocytic and bacteria-killing activity of leucocytes beyond that triggered by either agonist alone. On the other hand, IFN-γ enhances PAR2 agonist-induced monocyte chemoattractant protein 1 (MCP-1) secretion by human neutrophils and monocytes. Furthermore, phosphoinositide-3 kinase and janus kinase molecules are involved in the synergistic effect of PAR2 agonist and IFN-γ on MCP-1 secretion. Our findings suggest a potentially protective role of PAR2 agonists in the anti-microbial defence established by human monocytes and neutrophils.",
author = "Shpacovitch, {Victoria M.} and Micha Feld and Dirk Holzinger and Makiko Kido and Hollenberg, {Morley D.} and Francesca Levi-Schaffer and Nathalie Vergnolle and Stephan Ludwig and Johannes Roth and Thomas Luger and Martin Steinhoff",
year = "2011",
month = "7",
day = "1",
doi = "10.1111/j.1365-2567.2011.03443.x",
language = "English",
volume = "133",
pages = "329--339",
journal = "Immunology",
issn = "0019-2805",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Role of proteinase-activated receptor-2 in anti-bacterial and immunomodulatory effects of interferon-γ on human neutrophils and monocytes

AU - Shpacovitch, Victoria M.

AU - Feld, Micha

AU - Holzinger, Dirk

AU - Kido, Makiko

AU - Hollenberg, Morley D.

AU - Levi-Schaffer, Francesca

AU - Vergnolle, Nathalie

AU - Ludwig, Stephan

AU - Roth, Johannes

AU - Luger, Thomas

AU - Steinhoff, Martin

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Recent studies show that proteinase-activated receptor-2 (PAR2) contributes to the development of inflammatory responses. However, investigations into the precise role of PAR2 activation in the anti-microbial defence of human leucocytes are just beginning. We therefore evaluated the contribution of PAR2 to the anti-microbial response of isolated human innate immune cells. We found that PAR2 agonist, acting alone, enhances phagocytosis of Staphylococcus aureus and killing of Escherichia coli by human leucocytes, and that the magnitude of the effect is similar to that of interferon-γ (IFN-γ). However, co-application of PAR2-cAP and IFN-γ did not enhance the phagocytic and bacteria-killing activity of leucocytes beyond that triggered by either agonist alone. On the other hand, IFN-γ enhances PAR2 agonist-induced monocyte chemoattractant protein 1 (MCP-1) secretion by human neutrophils and monocytes. Furthermore, phosphoinositide-3 kinase and janus kinase molecules are involved in the synergistic effect of PAR2 agonist and IFN-γ on MCP-1 secretion. Our findings suggest a potentially protective role of PAR2 agonists in the anti-microbial defence established by human monocytes and neutrophils.

AB - Recent studies show that proteinase-activated receptor-2 (PAR2) contributes to the development of inflammatory responses. However, investigations into the precise role of PAR2 activation in the anti-microbial defence of human leucocytes are just beginning. We therefore evaluated the contribution of PAR2 to the anti-microbial response of isolated human innate immune cells. We found that PAR2 agonist, acting alone, enhances phagocytosis of Staphylococcus aureus and killing of Escherichia coli by human leucocytes, and that the magnitude of the effect is similar to that of interferon-γ (IFN-γ). However, co-application of PAR2-cAP and IFN-γ did not enhance the phagocytic and bacteria-killing activity of leucocytes beyond that triggered by either agonist alone. On the other hand, IFN-γ enhances PAR2 agonist-induced monocyte chemoattractant protein 1 (MCP-1) secretion by human neutrophils and monocytes. Furthermore, phosphoinositide-3 kinase and janus kinase molecules are involved in the synergistic effect of PAR2 agonist and IFN-γ on MCP-1 secretion. Our findings suggest a potentially protective role of PAR2 agonists in the anti-microbial defence established by human monocytes and neutrophils.

UR - http://www.scopus.com/inward/record.url?scp=79957838438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957838438&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2567.2011.03443.x

DO - 10.1111/j.1365-2567.2011.03443.x

M3 - Article

C2 - 21501162

AN - SCOPUS:79957838438

VL - 133

SP - 329

EP - 339

JO - Immunology

JF - Immunology

SN - 0019-2805

IS - 3

ER -